MORF4L2

Across TCGA pan-cancer cohorts, MORF4L2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MORF4L2 data layer compared with 24 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MORF4L2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MORF4L2 expression acts as an unfavorable survival marker.

CCRCC, PDAC, and LUAD are the cancer types where MORF4L2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	All	0.711	0.947	.004	45	view →
PDAC	OS	Median	II,III,IV	0.254	0.458	<.001	30	view →
LUAD	DFS	Quartile	All	0.619	0.864	.004	10	view →
OV	DFS	Median	All	0.674	0.923	.036	8	view →
HNSC	DFS	Quartile	All	0.333	1.000	.024	7	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MORF4L2–CCRCC (DFS)

Open the CCRCC breakdown →